Inclusion Criteria:

- Confirmed adenocarcinomas of the prostate.

- Evidence of metastatic disease

- Evidence of disease progression including one of the following: increasing levels of
PSA, progressive lymph node disease, or worsening bone scan

- PSA level is greater or equal to 7 ng/ml.

- ECOG performance status less than or equal to 1

Exclusion Criteria :

- Previously received bicalutamide, flutamide, or nilutamide within the past 12 months
(except for a period of use less than 30 days long).

- Prior chemotherapy for prostate cancer

- Prior rapamycin or rapamycin analogs, including ridaforolimus, everolimus, or
temsirolimus.

- Patient is receiving an opioid or narcotic analgesic for pain due to prostate cancer

- Patient has pain related to prostate cancer that warrants the initiation of
chemotherapy